- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT05293990
Usefulness of Gadovist-enhanced FLAIR Imaging
14. mars 2022 oppdatert av: Ryoo, In Seon
Usefulness of Gadovist-enhanced FLAIR Imaging in Differentiation Between a Glioblastoma and Solitary Brain Metastasis: Single Center Prospective Study
Polyplastic glioblastoma and metastatic brain cancer are the most common malignant brain tumors in adults.
The primary diagnostic test for tumors in the brain shows magnetic resonance imaging or similar imaging findings (especially single metastatic brain cancer) that make it difficult to distinguish between these two diseases.
In addition, due to the specificity of the tissue called the brain, biopsy is not easy and sometimes biopsy is difficult, so non-invasive discrimination is often important, and it is important how much prediction is made before the biopsy.
To solve this problem, various advanced magnetic resonance imaging techniques have been studied, but they are all tests that need to be additionally conducted on ordinary magnetic resonance images, and there are many subjective factors, so complex data and statistical processing methods, and many cannot be easily tested.
In addition, in all of these tests, accuracy is still reported at around 60%.
Therefore, if contrast-enhanced FLAIR images can be obtained along with contrast-enhanced T1 images performed during conventional magnetic resonance imaging tests to help differentiate between two diseases, it will greatly help diagnose and treat brain tumor patients and facilitate clinical application.
Studieoversikt
Status
Fullført
Detaljert beskrivelse
Polyplastic glioblastoma and metastatic brain tumors are the most common brain tumors in adults.
Polyplastic glioblastoma is the most common tumor among malignant primary brain tumors, and metastatic brain tumors are the most common brain tumors in adults.
In the diagnosis of brain tumors, magnetic resonance imaging is the most basic and primary imaging technique to date.
However, in the case of a single metastatic brain tumor, the tumor shape, signal intensity, contrast enhancement pattern, and peripheral signal intensity appear so similar that they are hardly distinguished from polymorphic glioblastoma in conventional magnetic resonance images.
However, it is very important to distinguish between the two diseases because the above two diseases have completely different characteristics in clinical aspects, surgical method decisions, treatment decisions, and prognosis.
Obtaining histological results will be the ultimate answer, but due to the nature of tissue called the brain, non-invasive tests are preferred, and sometimes patients (e.g., cardiovascular disease) or lesions themselves cannot handle surgery are in a very important part of the brain, so it depends on imaging techniques.
In addition, the distinction between the two diseases through imaging is important in that it is important to predict in advance even if biopsy is performed through surgery.
Therefore, various advanced magnetic resonance imaging techniques such as diffusion-enhanced imaging (DWI), perfusion imaging (perfusion), and spectroscopic imaging (MR spectroscopy) have been attempted to better differentiate the two diseases through imaging tests.
However, these images are additional imaging tests that need to be obtained after obtaining conventional magnetic resonance images and are usually accompanied by complex and various statistical analyses due to many subjective elements.
In addition, there are tests that are difficult to conduct other than large hospitals with a certain size or larger.
Nevertheless, the accuracy of the discrimination between the two diseases to date is around 60%.
In addition, such tests are often difficult to perform in most hospitals, except for large hospitals with a certain size or larger.
Therefore, if the two diseases can be better identified in conventional magnetic resonance imaging, it will be of great help to patient care clinically and it is expected that actual clinical application will be easier.
Contrast-enhanced T1 highlighted images are always performed in conventional magnetic resonance images, and after that, one more FLAIR image is obtained to see if contrast-enhanced FLAIR images are helpful in differentiating the two diseases.
Studietype
Intervensjonell
Registrering (Faktiske)
60
Fase
- Ikke aktuelt
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
Gurogu
-
Seoul, Gurogu, Korea, Republikken, 08308
- Korea University Guro Hospital
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
19 år og eldre (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion Criteria:
- All patients who undergo treatment, including surgery, after examining contrast-enhanced MR with an intra-brain mass that must exclude malignant tumors.
- Adults over 19 years of age at the time of examination
- Patients who agreed to this clinical study
Exclusion Criteria:
- In the case of severe cognitive of dysfunction or neurological defects (mRS>3)
- Pregnant or lactating patient
- Patients who are allergic to MRI contrast agents or cannot perform MRI for other reasons.
- Patients participating in other drug clinical trials as of the screening day (observation studies are possible)
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Diagnostisk
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Annen: Contrast-enhanced fluid attenuated inversion recovery
Confirmation of the difference between FLAIR contrast enhancement and T1 contrast enhancement patterns-->PACS monitor shows the maximum dimension of FLAIR and T1 contrast enhancement by two neurology radiologists on FLAIR and T1 contrast enhancement images.
In addition, the maximum diameter of the T2 high-signal lesion around the tumor is obtained using FLAIR images before contrast in the same plane.
(Dt2)
|
Usefulness of Gadovist-enhanced FLAIR imaging in differentiation between a glioblastoma and solitary brain metastasis
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Number of participants with treatment-related adverse events as assessed by axial FLAIR and axial spin-echo T1-weighted image
Tidsramme: about 5 year
|
Two 3.0 Tesla MR machines (MAGNETOM Trio A Tim and MAGNETOM Prisma; Siemens, Erlangen, Germany) were used in this study.
The protocol consisted of axial FLAIR (TR/TE/TI=9,000/100/2,500 milliseconds, with slice thickness of 2 mm) and axial spin-echo T1-weighted image (TR/TE=675/8.9
milliseconds, with slice thickness of 2 mm).
After both pre-enhancement images are acquired, CE-T1WI and CE-FLAIR sequences were obtained 5 and 10 minutes after administering gadolinium-based contrast agents, respectively.
Gadobutrol (Gadovist™, 0.1 millimol per kilogram of body weight, Schering AG, Berlin, Germany) was used as the contrast agent, via automated injector (Spectris MR; Medrad Europe, Maastricht, Netherlands).
Subtraction images for both CE-FLAIR and CE-T1WI sequences were also obtained.
Detailed protocol image sequence parameter is provided in shown in Online Resource 2.
|
about 5 year
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Etterforskere
- Hovedetterforsker: Ryoo In Seon, dotorate, Korea University Guro Hospital
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
2. februar 2017
Primær fullføring (Faktiske)
25. januar 2021
Studiet fullført (Faktiske)
25. januar 2021
Datoer for studieregistrering
Først innsendt
8. februar 2022
Først innsendt som oppfylte QC-kriteriene
14. mars 2022
Først lagt ut (Faktiske)
24. mars 2022
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
24. mars 2022
Siste oppdatering sendt inn som oppfylte QC-kriteriene
14. mars 2022
Sist bekreftet
1. mars 2022
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 2017GR0776
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Ondartede svulster
-
Ono Pharmaceutical Co. LtdRekruttering
-
Huabo Biopharm Co., Ltd.RekrutteringTumor, emnerForente stater, Kina
-
Istituto Clinico HumanitasFullført
-
Fudan UniversityRekruttering
-
Affiliated Hospital of Nantong UniversityPåmelding etter invitasjon
-
Peking University Third HospitalFullført
-
Bristol-Myers SquibbFullførtPan TumorForente stater, Puerto Rico, Italia, Argentina, Australia, Belgia, Canada, Chile, Danmark, Frankrike, Tyskland, Nederland, Polen, Romania, Singapore, Spania, Storbritannia
-
National Cancer Institute (NCI)RekrutteringMetastatisk Midgut Neuroendokrin Tumor | Ikke-opererbar Midgut Neuroendocrine Tumor | Metastatisk Midgut Neuroendocrine Tumor G1 | Metastatisk Midgut Neuroendocrine Tumor G2Forente stater, Canada
-
Incyte CorporationAvsluttetSolid tumor malignitetForente stater, Frankrike, Storbritannia, Italia, Korea, Republikken, Japan, Spania, Israel, Danmark, Tyskland, Sveits
-
Martin GutierrezHackensack Meridian Health; Karyopharm Therapeutics IncTilbaketrukket